Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 85

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 8
Chunk 85
---
genus Bot/Bal (see Note 3)40,815 (408)40,407 40,815 (408)40,407 Tolerance Therapeutics (Tzield®)25,461 (99)25,362 25,613 (101)25,512 Ohtuvayre inventors16,637 (156)16,481 15,969 (157)15,812 Elutia (CorMatrix)8,087 (1,487)6,600 9,418 (2,268)7,150 InvIOs1,396 (70)1,326 1,238 (62)1,176 Selexis186 (38)148 205 (58)147 Total financial royalty assets, net$206,620 $(2,788)$203,832 $198,587 $(3,538)$195,049 (1) The amounts of allowance include cumulated allowance for changes in expected cash flows and cumulated allowance for current expected credit losses.(2) The amounts include current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. The current portion of financial royalty assets amounted to $10.3 million and $10.0 million were presented in a separate line on our condensed consolidated balance sheets as of June 30, 2025 and December 31, 2024, respectively.Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired in the Apeiron Acquisition in July 2024, from Agenus in May 2024, Selexis, S.A. (“Selexis”) in April 2013 and May 2015, CorMatrix Cardiovascular, Inc. (“CorMatrix”) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. (“Elutia”) in September 2023) in 2017, Ovid Therapeutics Inc. (“Ovid”) in October 2023, Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) in November 2023, and from certain Ohtuvayre inventors in March 2024, August 2024 and January 2025.There was no impairment loss for the three and six months ended June 30, 2025. During three and six months ended June